Abiopharma

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

FuelCell Energy Secures $49 Million in EXIM Financing to Advance U.S. Clean Energy Exports

Almonty Industries Joins Large-Cap Russell 1000® Index and Broad-Market Russell 3000® Index

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves Disease

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Dyadic Expands IP Protection and Business Development Activities in Japan